Skip to content

Study · Observational study · n = 2 · 2024

5 results

Semaglutide-associated kidney injury.

Begum F, Chang K, Kapoor K, Vij R, Phadke G, Hiser WM, Wanchoo R, Sharma P, Sutaria N, Jhaveri KD

Clinical kidney journal13 Aug 2024Cited by 12 (Europe PMC)

PMID39258261 (opens in a new tab)PMCIDPMC11384876 (opens in a new tab)DOI10.1093/ckj/sfae250 (opens in a new tab)PepBankPUB-39258261
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are multipurpose agents effective in improving glycemic control in patients with type 2 diabetes while also achieving weight loss and risk reduction of major cardiovascular (CV) events and chronic kidney disease progression. With their increased utility in diabetes, obesity, CV health and renal protection, the use of GLP-1RAs has increased. However, with this increased use, there have also been increased reports of associated kidney adverse events, including case reports of acute interstitial nephritis (AIN) associated with GLP-1RA use. We report the data from the Food and Drug Administration adverse event reporting system (FAERS) in relation to GLP-1RA use and adverse kidney events, with acute kidney injury being the most common. In addition, we report two cases of semaglutide-associated biopsy-proven AIN and one with associated podocytopathy. To our knowledge, this is the first case of biopsy-proven AIN with podocytopathy associated with semaglutide use. Both patients experienced complete remission shortly after discontinuing semaglutide and undergoing immunosuppressive therapy. Further analysis of the FAERS database revealed 17 cases of proteinuria and 1 case of glomerulonephritis associated with semaglutide in the FAERS database, however no further information was available. While further research is needed to establish causality, this case series adds to the growing body of literature that semaglutide is associated with AIN and adds a new association, semaglutide with AIN and podocytopathies. While the overall clinical and mortality benefits of GLP-1RAs may outweigh the rarer risks, prescribers need to be aware of these associations, particularly as the use of GLP-1RAs continues to expand.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studySafety outcome

    In the FDA adverse event reporting system, 17 cases of proteinuria were associated with semaglutide.

    In plain wordsIn a database of adverse event reports, 17 cases of protein in the urine were linked to semaglutide; the reports do not prove cause.

    Peptide
    Semaglutide
    Outcome
    Not applicableProteinuria reports in FAERS
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Proteinuria cases
    17 cases
    FAERS

    Source sentences

    Summary
    Further analysis of the FAERS database revealed 17 cases of proteinuria and 1 case of glomerulonephritis associated with semaglutide in the FAERS database
  2. 02HumanObservational studySafety outcome

    In the FDA adverse event reporting system, 1 case of glomerulonephritis was associated with semaglutide.

    In plain wordsIn a database of adverse event reports, one case of kidney filter inflammation was linked to semaglutide; the reports do not prove cause.

    Peptide
    Semaglutide
    Outcome
    Not applicableGlomerulonephritis reports in FAERS
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Glomerulonephritis cases
    1 cases
    FAERS

    Source sentences

    Summary
    Further analysis of the FAERS database revealed 17 cases of proteinuria and 1 case of glomerulonephritis associated with semaglutide in the FAERS database
  3. 03HumanCase report or seriesSafety outcome

    Two patients had biopsy-proven acute interstitial nephritis associated with semaglutide, one with associated podocytopathy.

    In plain wordsTwo patients developed a kidney inflammation linked to semaglutide, one also with a kidney filter cell disease.

    Peptide
    Semaglutide
    Outcome
    Not applicableBiopsy-proven acute interstitial nephritis, one with podocytopathy
    Study

    n = 2

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, we report two cases of semaglutide-associated biopsy-proven AIN and one with associated podocytopathy.
  4. 04HumanCase report or seriesSafety outcome

    Both patients with semaglutide-associated kidney disease had complete remission shortly after semaglutide was stopped and immunosuppressive therapy was given.

    In plain wordsBoth patients recovered after semaglutide was stopped and they received immune-suppressing treatment, so the effect of stopping alone is unclear.

    Peptide
    Semaglutide
    Outcome
    Not applicableRemission after stopping semaglutide
    Study

    n = 2

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both patients experienced complete remission shortly after discontinuing semaglutide and undergoing immunosuppressive therapy.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 05HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In the FDA adverse event reporting system, adverse kidney events were reported with GLP-1 receptor agonists as a class, acute kidney injury being the most common.

    In plain wordsIn a database of adverse event reports, kidney problems were reported with GLP-1 drugs as a group, most often acute kidney injury.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse kidney events with GLP-1 receptor agonists in FAERS
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary

    Source sentences

    Summary
    We report the data from the Food and Drug Administration adverse event reporting system (FAERS) in relation to GLP-1RA use and adverse kidney events, with acute kidney injury being the most common.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.